SEARCH
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place to Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
FORTUNE 500
FORTUNE 500
FORTUNE SEA 500
Fortune 500 Europe
Fortune Global 500
Fortune China 500
Great Place to Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Banking
Investing
Crypto
Leadership
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
Ozempic
Ozempic
Health
Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients
By
Nick Lichtenberg
August 18, 2025
Commentary
Trump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud
By
Ari Yampolsky
and
Max Voldman
August 12, 2025
Newsletters
Exclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers
By
Emma Hinchliffe
August 7, 2025
C-Suite
Novo Nordisk selects insider Maziar Mike Doustdar as new CEO, to tackle ‘recent market challenges’
By
AFP
July 29, 2025
Finance
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
By
Jason Ma
June 17, 2025
Finance
Ozempic CEO’s exit from Novo started with Teams call surprise
By
Naomi Kresge
and
Bloomberg
May 16, 2025
Health
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
By
Ryan Hogg
May 9, 2025
Retail
Novo Nordisk slides on pressure from Lilly’s pill study
By
Marthe Fourcade
and
Bloomberg
April 22, 2025
Magazine
Ozempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?
By
Vivienne Walt
March 31, 2025
Finance
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
By
Chris Morris
March 7, 2025
Commentary
The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By
Wendy Barnes
March 4, 2025
Health
50-year-old security guard lost 70 pounds on Wegovy—then gained two pants sizes when he lost insurance coverage
By
Tom Murphy
and
The Associated Press
February 24, 2025
Health
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By
Bloomberg
,
Madison Muller
,
Ike Swetlitz
and
Naomi Kresge
February 21, 2025
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By
Lindsey Leake
February 11, 2025
Success
The wealthy 1% are turning to new status symbols that can’t be bought—and it’s hurting Dior, Versace, and Burberry
By
Emma Burleigh
February 7, 2025
Most Popular
Success
Millionaire Alexis Ohanian walked out of the LSAT 20 minutes in, went to a Waffle House, and decided he was ‘gonna...
By
Preston Fore
Success
Multimillion-dollar restaurant CEO used to splurge on Range Rovers and McLarens—but he’s reining it in now because...
By
Emma Burleigh
Finance
CEO who ran tech unicorn once valued at $1.2 billion charged with fraud after allegedly spending millions on his...
By
Amanda Gerut